Bone Metastases in NEN Patients - Frequency, Clinical, Therapeutic and Prognostic Relevance Abstract #1271

Introduction: Up to 73% of patients with neuroendocrine neoplasms (NEN) present with distant metastases at diagnosis. Advanced stage negatively correlates with prognosis. Bone metastases (BM) are usually reported in less than 10% of patients. Improved imaging results in more frequent detection but information in general is very limited.
Aim(s): Presentation of a single-center experience on frequency, clinical and therapeutic relevance of BM.
Materials and methods: All patients treated in the ENETs center in Marburg, Germany, between 2000 and June 2015 listed in our NEN-database were evaluated for inclusion. Out of 709 patients 414 had distant metastases (58.4 %) including 109 with BM (15.4%). 84 patients qualified for inclusion in our study.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Michael Scharf

To read results and conclusion, please login ...

Further abstracts you may be interested in

#825 Brain Metastases in Neuroendocrine Tumor Patients: Frequency and Outcome
Introduction: Brain metastases are rarely reported in patients with neuroendocrine carcinoma (NEC) of non-lung origin and neuroendocrine tumors (NETs) of the gastroenteropancreatic or bronchopulmonary system. Symptomatic brain metastases are associated with dismal prognosis, so early detection and treatment could be advisable.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. med. Anja Rinke
Authors: Rinke A, Müller D, König A, Arnold R, ...
#567 Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors
Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum
#111 Atypical lung carcinoid tumor metastatic to endocrine glands and bone marrow
Introduction: Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise 20% of all lung cancers. Typical low grade carcinoid tumors (TC) represent the majority of BP-carcinoids. Intermediate grade atypical carcinoid tumors (AC) are less often encountered but more aggressive. Although metastatic dissemination to mediastinal lymph nodes, liver, skeleton and central nervous system (CNS) is common, involvement of the endocrine glands has rarely been reported.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Vasiliki Daraki
#162 Different sites of rare metastases in neuroendocrine tumor patients detected by Ga-68 somatostatin receptor PET/CT
Introduction: The most common sites of metastases in neuroendocrine tumors are liver, lymph nodes, and bone.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Baum R P, ...
#1066 The Impact of Pharmacological-Mediated Depletion of Macrophages in Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of neuroendocrine neoplasms with distinct biological behaviour and response to treatment. Previous reports indicate that the infiltration of tumor-associated macrophages (TAMs) in PNETs strongly correlates with proliferation and metastases.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Sebastian Krug
Authors: Krug S, Abbassi R, Rinke A, Griesmann H, ...
Keywords: clodro, TAM, RIP1-Tag2
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.